KalVista Pharmaceuticals Inc Stock News

KalVista Pharmaceuticals, Inc. (KALV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm

KalVista Pharmaceuticals Inc (NASDAQ: KALV) prices its upsized underwritten public offering of 5.375 million at $36 per share, raising $193.5 million in gross proceeds. Earlier, the company offere

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 sha

Can this under-the-radar biotech and its hereditary angioedema candidate produce more gains for investors?

Analysts say the biotech's investors could be in store for even more gains.

Do favorable results in a mid-stage drug trial justify the stock of the developer more than doubling in a day?

Shares of KALV stock are blasting off on Tuesday after KalVista Pharmaceuticals reported strong results from its HAE treatment clinical trial. The post KALV Stock: 8 Things to Know About KalVista Phar

Shares of Kalvista Pharmaceuticals Inc (NASDAQ: KALV) are sharply higher Tuesday following the release of a mid-Phase clinical readout. What Happened: Kalvista, which focuses on developing small mole

Kalvista Pharmaceuticals Inc's (NASDAQ: KALV) oral plasma kallikrein inhibitor, KVD900, has reduced the use of rescue medication in patients suffering swelling attacks associated with hereditary a

The stock price of Kalvista Pharmaceuticals Inc (NASDAQ: KALV) is trading at over 100% pre-market. This is why it happened.

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that sm

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announc